

AMENDMENTS TO THE CLAIMS:

The following is a complete listing of the claims.

1. (Currently amended) A method to enhance the cytotoxicity of an antineoplastic drug against for the treatment of a disorder of abnormal cell proliferation, the method comprising administering an effective amount of the antineoplastic drug to a host in need of such treatment in combination with an effective cytotoxicity-increasing amount of an antioxidant, wherein the antioxidant is a mono-ester or di-ester of probucol.
- 2-18. (Cancelled)
19. (Currently amended) The method according to claim 18 1 wherein one or both of the hydroxyl groups of probucol are replaced with the mono-ester or di-ester of probucol is an esters ester of succinic acid, glutaric acid, adipic acid, suberic acid, sebacic acid, azelaic acid or maleic acid.
- 20-22. (Cancelled)
23. (Currently amended) The method of claim 1, 2, 3, 6 or 7, wherein the antineoplastic agent is selected from the group consisting of Aceglatone; Aclarubicin; Altretamine; Aminoglutethimide; 5-Aminolevulinic Acid; Amsacrine; Anastrozole; Ancitabine Hydrochloride; 17-1A Antibody; Antilymphocyte Immunoglobulins; Antineoplaston A10; Asparaginase; Pegaspargase; Azacitidine; Azathioprine; Batimastat; Benzoporphyrin Derivative; Bicalutamide; Bisantrene Hydrochloride; Bleomycin Sulphate; Brequinar Sodium; Broxuridine; Busulphan; Campath-IH; Caracemide; Carbemipime; Carboplatin; Carboquone; Carmofur; Carmustine; Chlorambucil; Chlorozotocin; Chromomycin; Cisplatin; Cladribine; Corynebacterium parvum; Cyclophosphamide; Cyclosporin; Cytarabine; Dacarbazine; Dactinomycin; Daunorubicin Hydrochloride; Decitabine; Diaziquone; Dichlorodiethylsulphide; Didemnin B.; Docetaxel; Doxifluridine; Doxorubicin Hycloride; Droloxifene; Echinomycin; Edatrexate; Elliptinium; Elmustine; Enloplatin; Enocitabine; Epirubicin Hydrochloride; Estramustine Sodium Phosphate; Etanidazole; Ethoglucid; Etoposide; Fadrozole

Hydrochloride; Fazarabine; Fenretinide; Floxuridine; Fludarabine Phosphate; Fluorouracil; Flutamide; Formestane; Fotemustine; Gallium Nitrate; Gencitabine; Gusperimus; Homoharringtonine; Hydroxyurea; Idarubicin Hydrochloride; Ifosfamide; Ilmofosine; Imrosulfan Tosylate; Inolimomab; Interleukin-2; Irinotecan; JM-216; Letrozole; Lithium Gamolenate; Lobaplatin; Lomustine; Lonidamine; Mafosfamide; Melphalan; Menogaril; Mercaptopurine; Methotrexate; Methotrexate Sodium; Miboplatin; Miltefosine; Misonidazole; Mitobronitol; Mitoguazone Dihydrochloride; Mitolactol; Mitomycin; Mitotane; Mitozantrone Hydrochloride; Mizoribine; Mopidamol; Multialchipeptide; Muromonab-CD3; Mustine Hydrochloride; Mycophenolic Acid; Mycophenolate Mofetil; Nedaplatin; Nilutamide; Nimustine Hydrochloride; Oxaliplatin; Paclitaxel; PCNU; Penostatin; Peplomycin Sulphate; Pipobroman; Pirarubicin; Piritrexim Isethionate; Piroxantrone Hydrochloride; Plicamycin; porfimer Sodium; Prednimustine; Procarbazine Hydrochloride; Raltitrexed; Ranimustine; Razoxane; Rogletimide; Roquinimex; Sebriplatin; Semustine; Sirolimus; Sizofiran; Sobuzoxane; Sodium Bromebrate; Sparfusic Acid; Sparfosate Sodium; Sreptozocin; Sulofenur; Tacrolimus; Tamoxifen; Tegafur; Teloxantrone Hydrochloride; Temozolomide; Teniposide; Testolactone; Tetrasodium Mesotetraphenylporphine-sulphonate; Thioguanine; Thioinosine; Thiotepa; Topotecan; Toremifene; Treosulfan; Trimetrexate; Trofosfamide; Tumor Necrosis Factor; Ubenimex; Uramustine; Vinblastine Sulphate; Vincristine Sulphate; Vindesine Sulphate; Vinorelbine Tartrate; Vorozole; Zinostatin; Zolimomab Aritox; and Zorubicin Hydrochloride.

24. (Cancelled)
25. (Cancelled)
26. (Currently amended) The method of claim 1, ~~2, 3 or 12~~, wherein the abnormal cell proliferation is a hyperproliferative or preneoplastic lesion.
- 27-30. (Cancelled)
31. (New) The method according to claim 1, wherein the antineoplastic drug is carboplatin.
32. (New) The method according to claim 1, wherein the antineoplastic drug is cisplatin.

33. (New) The method according to claim 1, wherein the antineoplastic drug is doxorubicin.
34. (New) The method according to claim 1, wherein the antineoplastic drug is daunorubicin.
35. (New) The method according to claim 1, wherein the mono- or di-ester of probucol is the mono-succinic acid ester.
36. (New) The method according to claim 1, wherein the mono- or di-ester of probucol is the mono-glutaric acid ester.
37. (New) The method according to claim 1, wherein the mono- or di-ester of probucol is the mono-adipic acid ester.
38. (New) The method according to claim 1, wherein the mono- or di-ester of probucol is the mono-suberic acid ester.
39. (New) The method according to claim 1, wherein the mono- or di-ester of probucol is the mono-azelaic acid ester.
40. (New) The method according to claim 1, wherein the mono- or di-ester of probucol is the mono-maleic acid ester.